Efocipegtrutide

DB18194InvestigationalProtein Based Therapies

Efocipegtrutide is a long-acting, monomeric peptide triple agonist.

Mechanism: Pharmacologically active on Glucagon receptor, Glucagon-like peptide 1 receptor, and Gastric inhibitory polypeptide receptor
Curator reviewed
Also known as: GLUCAGON ANALOG CONJUGATED WITH HUMAN IMMUNOGLOBULIN G4 FRAGMENT · HM15211 (LONG-ACTING GLP-1/GIP/GLUCAGON TRIPLE AGONIST) · IMMUNOGLOBULIN G4 (HUMAN .GAMMA.4-CHAIN C REGION C-TERMINAL FRAGMENT), DIMER, 1-(1-(3-HYDROXYPROPYL)-L-PROLINE), 1-ETHER WITH .ALPHA.-(3-((3-(3-MERCAPTO-2,5-DIOXO-1-PYRROLIDINYL)-1-OXOPROPYL)AMINO)PROPYL)-.OMEGA.-HYDROXYPOLY(OXY-1,2-ETHANEDIYL), THIOETHE
Code names: HM-15211

Resolves to

Compound

Targets

What you can answer from here — as of July 09, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Efocipegtrutide, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.